Related Experiment Video

Updated: Nov 17, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

6.0K

Dosage of anti-PD-1 monoclonal antibodies: a cardinal open question

M Sureda1, E Calvo2, J J Mata3

  • 1Plataforma de Oncología, Hospital Quironsalud Torrevieja, C/Partida de la Loma s/n, 03184, Torrevieja, Alicante, Spain. manuel.sureda@quironsalud.es.

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
|February 14, 2021
PubMed

Insights

Monoclonal antibodies like nivolumab and pembrolrolizumab have transformed cancer treatment. However, optimal dosing for these immunotherapies remains an open question, impacting their effectiveness and efficiency.

Area of Science:

  • Oncology
  • Immunotherapy
  • Pharmacology

Background:

  • Monoclonal antibodies targeting immune checkpoints have revolutionized cancer therapy.
  • Nivolumab and pembrolizumab are key examples with extensive clinical data.
  • Current dosing guidelines exist but may not be fully optimized.

Purpose of the Study:

  • To review the existing literature on nivolumab and pembrolizumab dosing.
  • To identify unresolved issues and areas for improvement in immunotherapy dosing.
  • To highlight the importance of optimizing dosing for enhanced treatment outcomes.

Main Methods:

  • Literature review of preclinical and clinical studies on nivolumab and pembrolizumab.
  • Analysis of published data regarding dosage regimens and their impact.
  • Synthesis of findings to identify knowledge gaps in immunotherapy dosing.

Main Results:

  • While approved dosages are established, significant questions persist regarding optimal dosing strategies.
  • Variability in patient response suggests potential for personalized dosing.
  • Further research is needed to refine dosing for improved efficacy and reduced toxicity.

Conclusions:

  • Dosing of nivolumab and pembrolizumab is an ongoing area of investigation.
  • Optimizing immunotherapy dosing is crucial for maximizing clinical benefit in oncology.
  • Addressing unresolved dosing questions is essential for advancing cancer treatment.
Keywords:
ImmunotherapyNivolumabPembrolizumabPersonalized dosage

More Related Videos

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

818
Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.5K

Related Concept Videos

Rational Dosage Regimen: Maintenance Dose and Loading Dose01:24

Rational Dosage Regimen: Maintenance Dose and Loading Dose

A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
4.9K
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
55
Drug Dosage Regimen: Overview01:15

Drug Dosage Regimen: Overview

A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
4.1K
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
71